• Теги
    • избранные теги
    • Компании206
      • Показать ещё
      Разное39
      • Показать ещё
      Страны / Регионы99
      • Показать ещё
      Международные организации4
      Издания1
      Показатели3
      Формат1
      Люди1
      Сферы1
11 июля, 23:19

Alnylam (ALNY) Stock Down Despite Positive Hemophilia Data

Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) specialty care global business unit, Genzyme, announced encouraging results from the ongoing phase II open-label extension (OLE) study.

08 июня, 16:47

BioMarin (BMRN) Down 8% Since Earnings Report: Can It Rebound?

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Выбор редакции
08 июня, 10:31

Why Is Alnylam (ALNY) Up 31.2% Since the Last Earnings Report?

Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

30 мая, 16:01

Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals

After declining in 2016, share price of French pharma giant Sanofi (SNY) has picked up in 2017.

Выбор редакции
Выбор редакции
08 мая, 20:59

Alnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y

Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.25 per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of $1.22 and the year-ago loss of $1.21.

05 мая, 17:37

Keryx (KERX) Q1 Loss Wider than Expected, Revenues Beat

Keryx Biopharmaceuticals Inc. (KERX) reported first-quarter 2017 loss of 21 cents per share, narrower than the year-ago loss of 39 cents

05 мая, 17:30

BioMarin (BMRN) Posts Earnings in Q1, Sales Top, Stock Up

BioMarin Pharmaceutical Inc. (BMRN) reported earnings of 3 cents per share in the first quarter of 2017.

28 апреля, 16:19

Sanofi (SNY) Q1 Earnings Top, Sales Rise Y/Y, Shares Up

Sanofi (SNY) reported first-quarter 2017 earnings of 75 cents per American depositary share, which beat the Zacks Consensus Estimate of 73 cents by 2.7%.

29 марта, 17:21

Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod

Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic dermatitis (AD).

28 марта, 14:10

Why Is BioMarin (BMRN) Down 2.2% Since the Last Earnings Report?

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Выбор редакции
23 марта, 13:16

Alnylam (ALNY) Up 14.5% Since Earnings Report: Can It Continue?

Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

17 марта, 01:12

Keryx Focuses on Kidney Drug Aurexia Despite Generic Threat

We issued an updated research report on Keryx Biopharmaceuticals, Inc. (KERX) on Mar 15, 2017.

08 марта, 17:45

Ionis Pharma Lipid Disorder Candidate Positive in Phase III

Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, Inc. (IONS), recently announced positive results from a pivotal phase III study evaluating its pipeline candidate volanesorsen for treatment of patients with familial chylomicronemia syndrome.

24 февраля, 17:41

BioMarin (BMRN) Q4 Loss Narrower than Expected; Sales Beat

BioMarin Pharmaceutical Inc. (BMRN) reported a loss of 37 cents per share in the fourth quarter of 2016.

09 февраля, 19:07

Alnylam (ALNY) Q3 Loss Narrower than Expected, Revenues Rise

Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.32 per share in the fourth quarter of 2016, narrower than both the Zacks Consensus Estimate loss of $1.35 and the year-ago loss of $1.07.

09 февраля, 16:33

Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now

Sanofi (SNY) reported fourth-quarter 2016 earnings of 67 cents per American depositary share, which was in line with the Zacks Consensus Estimate.

07 февраля, 17:06

Drug Stock Q4 Earnings to Watch on Feb 8: AGN, GSK & More

How will these four drug stocks, AGN, GSK, ALNY and SNY, which are all scheduled to report Q4 results on Feb 8, fare this earnings season?

Выбор редакции
23 января, 14:32

Инновационный препарат для лечения рассеянного склероза становится более доступным

Препарат Lemtrada, выпускаемый фармацевтической компанией Sanofi Genzyme, был включен в государственную корзину медицинских услуг еще пару лет назад, но в 2017 году критерии его назначения стали более широкими.

11 января, 02:25

Sanofi, ImmuNext Ink Deal, Focus on Autoimmune Diseases

Sanofi (SNY) announced an agreement with ImmuNext, Inc. for the development of a novel antibody to treat a range of autoimmune diseases including lupus and multiple sclerosis.